MicroPort Orthopedics and Pixee Medical Expanded Partnership and Combined Demo at AAHKS

MicroPort Orthopedics Evolution® Medial-Pivot Knee Implant and Pixee Medical Knee+* platform demo at AAHKS 2022

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, today announces the expansion of its partnership with Pixee Medical through the commercialization of its combined surgical solution in the United States. Utilizing Pixee Medical’s FDA-cleared augmented reality surgical application for assistance in total knee arthroplasty, the surgeon can achieve precision and control when implanting MicroPort Evolution® Medial-Pivot Knee Implant. This solution is currently being used in thousands of successful cases around the world including in Australia, Europe, and Asia.

The MicroPort Orthopedics Evolution® Medial-Pivot Knee Implant delivers a high degree of stability and motion, leading to increased patient satisfaction1 and survivorship1. The Pixee Medical Knee+ is a patented platform designed to assist orthopedic surgeons to perform surgeries better and faster by providing real-time positioning of instruments, right in their field of view via smart glasses.

Combining MicroPort’s innovative devices with Pixee Medical’s platform is allowing patients, worldwide, access to surgery solutions integrating top of the class technologies.

This technology will be presented for the first time to U.S. surgeons at the Annual 2022 AAHKS meeting from November 3 to 6. Demos of Pixee’s technology will be available at MicroPort’s booth, #615. In addition, MicroPort will be hosting a symposium on Friday, November 4th, titled “Trends and Controversies in Hips, Knees, and the ASC,” where surgeon leaders will be discussing advances in arthroplasty.

“After much success around the world, we are excited to bring Pixee’s transformative technology to the United States for continued efficiency and precision of our device systems,” said Rob Cripe, Chief Commercial Officer at MicroPort Orthopedics. “Our mission at MicroPort is to help the patient achieve Full Function, Faster® – and the enhanced precision and efficiency this technology provides will help ensure this happens.”

“Combining MicroPort’s innovative devices and our platform is allowing patients, worldwide, access to surgery solutions that provide them with a faster recovery,” said Sébastien Henry, CEO at Pixee Medical. “Companies partnering in this orthopedic ecosystem are providing options to patients that weren’t available before now to improve their recovery and overall quality of life.”

MicroPort Orthopedics offers products and techniques to help patients receiving total hip and knee replacements achieve Full Function, Faster®. For more information, visit www.microportortho.com.

*MicroPort is acting as a distributor for these products and not as a sales agent for Pixee Medical.

1. Based on a retrospective study of Advance® Medial-Pivot. Macheras GA et al A long term clinical outcome of the Medial Pivot Knee Arthroplasty System. Knee. 2017 Mar.; 24(2):447-453

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.